Retrospective Study Of Stem Cell Transplantation For Acute Myeloid Leukemia (aml): The Brazilian Experience [estudo Retrospectivo Do Tratamento De Leucemia Mielóide Aguda Com O Transplante De Medula óssea - A Experiência Brasileira]

Data from the International Bone Marrow Transplant Registry (IBMTR) contribute for the improvement of Bone Marrow Transplant (BMT) worldwide. We studied the Brazilian experience in BMT for AML to compare this with international data. We performed a retrospective study by sending questionnaires to 16 BMT centers regarding clinical and treatment variables. Statistical analyses concerning autologous BMT (autoBMT) and allogeneic BMT (alloBMT) were performed using the Kaplan-Meier method and the log-rank test. All p-values were two-tailed. We collected data from 731 patients (205 autoBMT and 526 alloBMT). Median overall survival (OS) for autoBMT patients was longer than alloBMT patients (1035 vs. 466 days, p=0.0012). AlloBMT stem cell source (SCS): 73% bone marrow stem cell (BMSC), 23% peripheral blood stem cells (PBSC) and 4% umbilical cord blood. Among the autoBMT patients, the SCS was 63% PBSC, 22% BMSC and 15% both. The SCS did not impact on OS. There was no difference in OS between different FAB classifications in the alloBMT group, but in the autoBMT the M3 patients had longer survival. As expected, the main cause of mortality among autoBMT patients was related to disease relapse (60%), while in the alloBMT, to infection (38%). In both groups we found longer OS in first complete remission (1CR) compared to second (2CR) and other (p<0.0001), and longer OS in de novo AML than in secondary. In the alloBMT group we found more patients with advanced disease (60%), while in the autoBMT group, we found more M3 patients (24%), which could explain the difference in OS. Most of our results are in accordance with IBMTR data. One should consider the fact that this is a retrospective study and our findings should be analysed with caution.2811118Scheinberg, D.A., Maslak, P., Weiss, M., Acute leukemias (2001) Cancer: Principles and Practice of Oncology. 6th Ed., pp. 2.404-32. , DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Philadelphia, Pa: Lippincott Williams & WilkinsMyint, H., Lucie, N.P., The prognostic significance of the CD34 antigen in acute myeloid leukaemia (1992) Leuk Lymphoma, 7 (5-6), pp. 425-429Geller, R.B., Zahurak, M., Hurwitz, C.A., Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: The significance of the stem-cell glycoprotein CD34 (My10) (1990) Br J Haematol, 76 (3), pp. 340-347Campos, L., Guyotat, D., Archimbaud, E., Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis (1992) Blood, 79 (2), pp. 473-476Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study (2000) Blood, 96 (13), pp. 4075-4083Grimwade, D., Walker, H., Harrison, G., The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial (2001) Blood, 98 (5), pp. 1312-1320Mrózek, K., Prior, T.W., Edwards, C., Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B Study (2001) J Clin Oncol, 19 (9), pp. 2482-2492Brunning, R.D., Matutes, E., Harris, N.L., Acute myeloid leukaemia: Introduction (2001) World Health Organization Classification of Tumours, 3, pp. 77-80. , Jaffe ES, Harris NL, Stein H, et al., eds.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC PressBennett, J.M., Catovsky, D., Daniel, M.T., Proposals for the classification of the acute leukaemias (1976) Br J Haematol, 33 (4), pp. 451-458. , French-American-British (FAB) co-operative groupCheson, B.D., Cassileth, P.A., Head, D.R., Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia (1990) J Clin Oncol, 8 (5), pp. 813-819Micallef, I.N., Rohatiner, A.Z., Carter, M., Long-term outcome of patients surviving for more than ten years following treatment for acute leukaemia (2001) Br J Haematol, 113 (2), pp. 443-445Scheinberg, D.A., Maslak, P., Weiss, M., Acute leukemias (2001) Cancer: Principles and Practice of Oncology. 6th Ed., pp. 2404-2432. , DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Philadelphia, Pa: Lippincott Williams & WilkinsWiernik, P.H., Diagnosis and treatment of acute nonlymphocytic leukemia (1996) Neoplastic Diseases of the Blood. 3rd Ed., pp. 283-302. , Wiernik PH, Canellos GP, Dutcher JP, et al., eds.: New York, NY: Churchill LivingstoneWiernik, P.H., Banks, P.L., Case Jr., D.C., Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia (1992) Blood, 79 (2), pp. 313-319Cassileth, P.A., Lynch, E., Hines, J.D., Varying intensity of postremission therapy in acute myeloid leukemia (1992) Blood, 79 (8), pp. 1.924-30Vaughan, W.P., Karp, J.E., Burke, P.J., Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia (1980) Cancer, 45 (5), pp. 859-865Cassileth, P.A., Harrington, D.P., Hines, J.D., Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia (1988) J Clin Oncol, 6 (4), pp. 583-587Mayer, R.J., Davis, R.B., Schiffer, C.A., Intensive postremission chemotherapy in adults with acute myeloid leukemia (1994) N Engl J Med, 331 (14), pp. 896-903. , Cancer and Leukemia Group BChamplin, R., Gajewski, J., Nimer, S., Postremission chemotherapy for adults with acute myelogenous leukemia: Improved survival with highdose cytarabine and daunorubicin consolidation treatment (1990) J Clin Oncol, 8 (7), pp. 1.199-206Clift, R.A., Buckner, C.D., Thomas, E.D., The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation (1987) Bone Marrow Transplant, 2 (3), pp. 243-258Reiffers, J., Gaspard, M.H., Maraninchi, D., Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: A prospective controlled trial (1989) Br J Haematol, 72 (1), pp. 57-63Bostrom, B., Brunning, R.D., McGlave, P., Bone marrow transplantation for acute non-lymphocytic leukemia in first remission: Analysis of prognostic factors (1985) Blood, 65 (5), pp. 1.191-6Busca, A., Anasetti, C., Anderson, G., Unrelated donor or autologous marrow transplantation for treatment of acute leukemia (1994) Blood, 83 (10), pp. 3.077-84Tallman, M.S., Rowlings, P.A., Milone, G., Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission (2000) Blood, 96 (4), pp. 1.254-8Cassileth, P.A., Andersen, J., Lazarus, H.M., Autologous bone marrow transplant in acute myeloid leukemia in first remission (1993) J Clin Oncol, 11 (2), pp. 314-319Jones, R.J., Santos, G.W., Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging (1990) Acute Myelogenous Leukemia: Progress and Controversies: Proceedings of a Wyeth-Ayerst-UCLA Symposia Western Workshop, pp. 411-419. , Gale RP, ed.: Held at Lake Lanier, Georgia, November 28-December 1, 1989. New York: Wiley-LissGorin, N.C., Aegerter, P., Auvert, B., Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging (1990) Blood, 75 (8), pp. 1.606-14Zittoun, R.A., Mandelli, F., Willemze, R., Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia (1995) N Engl J Med, 332 (4), pp. 217-223. , European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative GroupsFerrant, A., Labopin, M., Frassoni, F., Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study (1997) Blood, 90 (8), pp. 2.931-8. , Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Schiller, G.J., Nimer, S.D., Territo, M.C., Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission (1992) J Clin Oncol, 10 (1), pp. 41-46Witherspoon, R.P., Deeg, H.J., Storer, B., Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia (2001) J Clin Oncol, 19 (8), pp. 2.134-4